200,000+ products from a single source!
sales@angenechem.com
Home > Indoles and Oxindole > 114719-57-2
114719-57-2 | Pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-, chloride
CAS No: 114719-57-2 Catalog No: AG000F3H MDL No:
Product Description
Catalog Number:
AG000F3H
Chemical Name:
Pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-, chloride
CAS Number:
114719-57-2
Molecular Formula:
C18H11ClN2O
Molecular Weight:
306.7457
IUPAC Name:
3-aza-13-azoniapentacyclo[11.7.0.02,10.04,9.014,19]icosa-1(13),2(10),4,6,8,11,14,16,18-nonaen-20-one;chloride
InChI:
InChI=1S/C18H10N2O.ClH/c21-18-13-6-2-4-8-15(13)20-10-9-12-11-5-1-3-7-14(11)19-16(12)17(18)20;/h1-10H;1H
InChI Key:
PWUOOJVYZQILBG-UHFFFAOYSA-N
SMILES:
O=C1c2c3[nH]c4c(c3cc[n+]2c2c1cccc2)cccc4.[Cl-]
NSC Number:
622398
Properties
Complexity:
451
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
306.056g/mol
Formal Charge:
0
Heavy Atom Count:
22
Hydrogen Bond Acceptor Count:
2
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
306.749g/mol
Monoisotopic Mass:
306.056g/mol
Rotatable Bond Count:
0
Topological Polar Surface Area:
36.7A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| A marine sponge alkaloid derivative 4-chloro fascaplysin inhibits tumor growth and VEGF mediated angiogenesis by disrupting PI3K/Akt/mTOR signaling cascade. | Chemico-biological interactions 20170925 |
| Chemistry and biology of fascaplysin, a potent marine-derived CDK-4 inhibitor. | Mini reviews in medicinal chemistry 20120601 |
| Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling. | PloS one 20120101 |
| 3-bromohomofascaplysin A, a fascaplysin analogue from a Fijian Didemnum sp. ascidian. | Bioorganic & medicinal chemistry 20111115 |
| Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20110717 |
| Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20101001 |
| Silver catalyzed cascade synthesis of alkaloid ring systems: concise total synthesis of fascaplysin, homofascaplysin C and analogues. | Chemical communications (Cambridge, England) 20100707 |
| Antimalarial and antitubercular nostocarboline and eudistomin derivatives: synthesis, in vitro and in vivo biological evaluation. | Bioorganic & medicinal chemistry 20100215 |
| [Anti-proliferation of human cervical cancer HeLa cell line by fascaplysin through apoptosis induction]. | Yao xue xue bao = Acta pharmaceutica Sinica 20090901 |
| Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1. | Bioorganic & medicinal chemistry 20090815 |
| Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment. | Current medicinal chemistry 20090101 |
| Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. | Bioorganic & medicinal chemistry 20080815 |
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. | Proceedings of the National Academy of Sciences of the United States of America 20071218 |
| Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo. | Cancer chemotherapy and pharmacology 20070301 |
| Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors. | Organic & biomolecular chemistry 20061221 |
| Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin. | Bioorganic chemistry 20061001 |
| Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia. | The American journal of pathology 20060901 |
| CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation. | Bioorganic & medicinal chemistry letters 20060815 |
| Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin. | Organic & biomolecular chemistry 20060307 |
| A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets. | Journal of natural products 20060101 |
| New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity. | Chemical communications (Cambridge, England) 20040807 |
| Cytotoxic alkaloids from the marine sponge Thorectandra sp. | Natural product research 20040601 |
| Comparison of fascaplysin and related alkaloids: a study of structures, cytotoxicities, and sources. | Journal of natural products 20040501 |
| Langerhans cell histiocytosis immunohistochemical expression of fascin, a dendritic cell marker. | American journal of clinical pathology 20020901 |
| DNA binding properties of the marine sponge pigment fascaplysin. | Bioorganic & medicinal chemistry 20010401 |
| Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. | Biochemical and biophysical research communications 20000907 |
| A new bioactive sesterterpene and antiplasmodial alkaloids from the marine sponge hyrtios cf. erecta. | Journal of natural products 20000601 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.